High Tide's Remexian Hits Record 7.6-Tonne Quarter in German Cannabis

Germany's medical cannabis market keeps rewriting records, and Canadian cannabis retailer High Tide just put up its biggest quarter yet on the other side of the Atlantic. The Calgary-based company announced that its 51%-owned subsidiary, Remexian Pharma GmbH, distributed approximately 7.6 tonnes of medical cannabis into the German market during the second fiscal quarter ended April 30, 2026 — the highest quarterly distribution volume in Remexian's history. The disclosure feeds into a story investors have been watching all year: how fast Germany's reformed medical cannabis system can grow, and which operators are best positioned to take share.

The High Tide Germany 7.6 tonnes figure represents a 21% sequential increase over the prior quarter and a 49% increase year-over-year, according to the preliminary tonnage data High Tide disclosed in early May. The company cautioned that the figures are preliminary, unaudited, and subject to revision until the full Q2 financial statements are released in June 2026. Even so, the magnitude of the jump is hard to dismiss as noise.

When you're ready to find a cannabis dispensary near you, Budpedia is the dispensary near me directory built around verified listings, real menus, and city-by-city coverage.

Why Germany Is Suddenly the Engine of European Cannabis

Germany imported roughly 201.1 tonnes of medical cannabis in 2025 — more than double the prior year's 72.9 tonnes — after the country's 2024 reform partially decriminalized possession and overhauled medical access. Pharmacy-dispensed medical cannabis can now reach a broader pool of patients via telemedicine consultations and electronic prescriptions, and growth has tracked the regulatory liberalization closely.

What that means in practical terms: Germany is now the largest legal medical cannabis market in Europe by a wide margin, the gateway for cannabis exports from Canada, Portugal, Spain, Denmark, and a growing list of African countries, and one of the few markets where wholesale prices and volumes are both rising at the same time. For a Canadian operator like High Tide, owning a distribution channel into that market is roughly the equivalent of owning a tollbooth on a road that is widening month over month.

Remexian's 7.6-tonne quarter equates to a market share north of 10% of Germany's imported tonnage — making it one of the largest single distributors of medical cannabis in the country. It also underscores a structural advantage High Tide has been building since announcing the Remexian acquisition: vertical integration into a market where the demand growth is driven by regulation rather than by hype.

What This Says About High Tide's Strategy

High Tide is better known to North American investors for its Canna Cabana retail footprint — a roughly 200-store discount cannabis retailer that competes on price in saturated provincial markets. The Remexian story is a deliberate diversification away from that thesis. Where Canna Cabana faces margin compression and Canadian excise-tax pressures, Remexian operates in a regulated wholesale market with growing volumes and relatively healthier unit economics.

The CEO has previously framed Germany as one of two pillars supporting the company's near-term growth, alongside the rollout of cannabis-adjacent products and U.S. CBD distribution. The 7.6-tonne disclosure is consistent with that pitch. Crucially, it is also consistent with broader analyst commentary suggesting High Tide is one of the few cannabis names with an actual organic growth story rather than a pure rescheduling-narrative trade.

Investors should still watch a few things. Preliminary tonnage figures are not revenue figures. Wholesale pricing in Germany has been competitive and, in some product categories, falling. And the German government's regulatory posture toward cannabis can still shift — the country's 2024 reform has critics within the medical community and in some federal-state coalitions. None of these caveats negate the Q2 jump, but they shape how much credit to give it.

Context: Other Operators Moving on Germany

High Tide is hardly alone in chasing the German opportunity. In 2026, multiple international players have been expanding capacity, signing new distribution agreements, or rolling out novel product formats designed for the German pharmacy channel. Curaleaf U.K. recently launched the first cannabis-based pessaries and suppositories specifically for pelvic and menstrual health, expanding its U.K. and German distribution. Tilray Brands continues to expand its European footprint with new pharmaceutical partnerships, and several Canadian and Portuguese cultivators have re-tooled for the German market specifically.

What separates Remexian's quarter is volume share. Sub-10% market share in a rapidly growing market is interesting; double-digit share in the largest medical cannabis market in Europe is structurally meaningful. If Germany's market continues to compound at anything close to its 2025 pace, the leaders will set wholesale norms — pricing, packaging standards, supply-chain expectations — that smaller competitors will be forced to follow.

What's Next for HITI Stock and the Numbers to Watch

For HITI stock 2026 watchers, the next concrete catalyst is the full Q2 FY2026 financial release in June 2026. That report will translate the 7.6 tonnes into euros and (after currency conversion) Canadian dollars, will reveal gross margins on the German business specifically, and will provide updated guidance for the second half. Analysts will be looking for: (1) average wholesale price per gram in Germany, (2) Remexian gross margin, (3) cash conversion from the German business, and (4) any incremental capacity announcements.

Beyond the Remexian print, the company's North American retail trajectory and U.S. CBD distribution are the other two legs. A clean German number paired with stable Canadian retail and continued U.S. CBD growth would broadly validate the diversification thesis. A strong German number paired with weakness elsewhere would force a tougher conversation about how much investors should pay for the German exposure alone.

What It Means for the Industry

Zoom out and the implication is bigger than any single ticker. Germany is starting to function the way analysts once hoped Canada and select U.S. states would: a regulated medical channel, growing on its own, with measurable patient counts and predictable distribution. The 7.6-tonne quarter is one data point, but the trajectory it sits on — 201.1 tonnes imported in 2025, up from 72.9 the prior year — is the part that matters. Several major cannabis operators now derive a non-trivial share of their growth from a single European country.

For dispensary operators in the U.S., the lesson is more sobering: while domestic price compression continues, the most reliable growth in 2026 is happening overseas, in a market that did not even meaningfully exist five years ago. Capital is starting to notice.

Key Takeaways

• High Tide's 51%-owned subsidiary Remexian Pharma GmbH distributed approximately 7.6 tonnes of medical cannabis into Germany during Q2 FY2026 — a record for the company.
• Volumes were up roughly 21% sequentially and 49% year-over-year. Figures are preliminary and unaudited until June 2026.
• Germany imported about 201.1 tonnes of medical cannabis in 2025, more than double the prior year, making it the largest medical cannabis market in Europe.
• Remexian's share now exceeds 10% of imported tonnage, positioning the company as a top distributor in the country.
• For HITI investors, the next major catalyst is the full Q2 FY2026 financial release in June 2026, which will translate tonnage into revenue and margin.

Explore cannabis news, find dispensaries, and join the community at Budpedia.